14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today RGLS ranks #15172 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Regulus Therapeutics Inc. Stock Forecast NASDAQ:RGLS

$0.38 (3.88%)

Volume: 871k

Closed: Dec 08, 2021

Hollow Logo Score: -2.419

Regulus Therapeutics Inc. Stock Forecast

$0.38 (3.88%)

Volume: 871k

Closed: Dec 08, 2021

Score Hollow Logo -2.419
Which way will RGLS go? Request
Key Stats
Beta 1
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 43 and the stock is currently not being overbought or oversold

Regulus Therapeutics Inc. stock price up 3.88% on Wednesday
(Updated on Dec 08, 2021)

Sell candidate since 2021-10-12 Loss -49.92%

The Regulus Therapeutics Inc. stock price gained 3.88% on the last trading day (Wednesday, 8th Dec 2021), rising from $0.37 to $0.38. , and has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 8.33% from a day low at $0.36 to a day high of $0.39. The price has risen in 6 of the last 10 days and is up by 5.46% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 240 thousand more shares were traded than the day before. In total, 871 thousand shares were bought and sold for approximately $331.23 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -51.38% during the next 3 months and, with a 90% probability hold a price between $0.14 and $0.22 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, December 03, 2021, and so far it has risen 11.88%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Regulus Therapeutics Inc. has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Regulus Therapeutics Inc. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.42. On a fall, the stock will find some support from the short-term average at $0.36. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Support, Risk & Stop-loss

Regulus Therapeutics Inc. finds support from accumulated volume at $0.36 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0300 between high and low, or 8.33%. For the last week, the stock has had a daily average volatility of 7.97%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Regulus Therapeutics Inc. stock A Buy?

Regulus Therapeutics Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.419

Predicted Opening Price for Regulus Therapeutics Inc. of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$0.38 $0.38 (Overvalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Sep 02, 2021 "Cantor Fitzgerald" gave "" rating for RGLS. The price target was set to $0.81+4.0%.

Volatility and Risk
Daily Average Volatility: 7.97 %
Overall Risk: Very High High Medium Low Very Low
7.97 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $0.44
Price: $0.38
Support: $0.36

RGLS Insider Trading Show all Trades



Last 100 transactions
Buy: 153 305 057 | Sell: 236 273 (Shares)
Date Action Amount Person Type
Nov 30, 2021 Buy 2 222 222 Papadopoulos Stelios Common Stock
Jun 14, 2021 Buy 40 000 Nunn Jason Raleigh Stock Option (Right to Buy)
Jun 14, 2021 Buy 40 000 Simeonidis Simos Stock Option (Right to Buy)
Jun 14, 2021 Buy 40 000 Rosen Hugh Stock Option (Right to Buy)
Jun 14, 2021 Buy 40 000 Witz Pascale Stock Option (Right to Buy)
Show all Insider Trades


Last 100 transactions
Buy: 153 305 057 | Sell: 236 273 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.41 6.94 %
0.40 3.93 %
0.39 2.07 %
Current price: 0.38
Support 0.37 -3.96 %
0.36 -5.82 %
0.35 -8.83 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.47 24.66 %
0.46 22.03 %
0.44 15.93 %
Current price 0.38
Support 0.36 -4.81%
0.36 -5.18%
0.36 -5.89%

Click to get the best stock tips daily for free!

About Regulus Therapeutics Inc.

Regulus Therapeutics Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus i... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE